For the typically young and active desmoid tumor patient population, the convenience of a once-daily oral pill is a major advantage. This seemingly simple feature significantly improves compliance and adherence compared to twice-daily regimens, making it a key factor in real-world treatment feasibility and success, more so than the specific milligram dosage.

While the gut instinct is that patients prefer daily pills over injections, this preference flips when the injection is highly infrequent. For chronic conditions, a quarterly shot (four per year) is often viewed as more convenient and favorable by patients than the burden of a daily oral medication, challenging conventional wisdom on administration routes.

ADT monotherapy is an obsolete strategy for metastatic prostate cancer. For patients too frail for standard ADT+ARPI combination therapy, enzalutamide monotherapy is a superior alternative. It offers effective treatment that can be quickly stopped to reverse side effects if tolerance issues arise, unlike injectable ADT.

The development of SERDs for adjuvant therapy was stalled for two decades not by efficacy concerns, but by logistics. Fulvestrant, the first SERD, required monthly intramuscular injections, a pragmatically unfeasible strategy for a 5-year adjuvant trial, a problem only solved with the advent of oral SERDs.

The HERO trial found the GnRH antagonist relugolix reduced major adverse cardiovascular events (MACE) by 54% compared to the agonist leuprolide. While absolute rates were low (2.8% vs 5.6%), this suggests a significant safety advantage for antagonists in patients with cardiovascular risk.

The oral GnRH antagonist Relagolix allows for much quicker testosterone recovery (1-2 months vs. 3-6 for leuprolide). While beneficial in curative-intent settings, this rapid recovery is a double-edged sword that could shorten the "off-therapy" period during intermittent treatment for metastatic disease.

A drug-drug interaction study found that apalutamide induces an enzyme (CYP3A4) that lowers relagolix concentrations, leading to suboptimal hormonal suppression. To maintain efficacy when used in combination, the standard dose of the oral GnRH antagonist relagolix must be doubled.

New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.

The oral antagonist relugolix allows for rapid testosterone recovery after discontinuation. While useful for planned intermittent therapy, a case study shows this can be a clinical pitfall. In non-adherent patients who self-discontinue, it can lead to an equally rapid rise in PSA and disease progression.